Company Overview and News
Here's a monthly recap of the top news in the gold mining sector, including acquisitions and takeover announcements, financial results and other relevant updates, to keep readers up-to-date on news in the sector. Here's my update for May, in case you missed it.
AGCBF RIO RIO YRI KGI.DB CG CAGDF RTPPF FPC AUY OR RTNTF FPRGF SEMFF KL WPM SAND SSL SDDXF KGI OKSWF KGI.DB.A SNXZF RGLD AGC RIO OSKGF RGL
TORONTO, July 03, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) is pleased to report that it has completed the previously-announced sale of a perpetual 1.75% Net Smelter Return Royalty (the “Royalty”) on the Mara Rosa gold project (the “Mara Rosa Project”) to RG Royalties, LLC, a wholly-owned subsidiary of Royal Gold, Inc. (NASDAQ:RGLD) (“Royal Gold”), for USD $10.
AGCBF RGLD AGC RGL
TORONTO, June 29, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) today announces the entry into an agreement for sale of a perpetual 1.75% Net Smelter Return Royalty on the Mara Rosa gold project (the “Royalty Agreement”) to RG Royalties, LLC, a wholly-owned subsidiary of Royal Gold, Inc. (NASDAQ:RGLD) (“Royal Gold”), for USD $10.8 million (approximately CAD$14.
AGCBF RGLD AGC RGL
TORONTO, ON / ACCESSWIRE / June 15, 2018 / Amarillo Gold Corporation (TSXV: AGC) ("Amarillo" or the "Company") today announces that the Company will be presenting at the MicroCap Conference on June 21st in Toronto and at the John Tumazos Conference in New Jersey June 28th, 2018.
TORONTO, June 13, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) previously announced on May 23, 2018 that it had commenced a 10,000m drill program on its flagship Mara Rosa Project. The assay results reported in Table 1 below are from four geotechnical holes drilled in 2011, but only now assayed as part of this new campaign.
TORONTO, June 11, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) is pleased to announce that Marc Ducharme has been appointed Chief Exploration Geologist. Mr. Ducharme is a geologist with over thirty years of experience in the minerals industry, managing and conducting exploration programs from grass roots through to advanced stage exploration and feasibility stage projects.
AGCBF AGC WDO WDOFF
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
* AMARILLO GOLD - PROPOSING TO COMPLETE NON-BROKERED PRIVATE PLACEMENT OF UNITS AT $0.28 PER UNIT FOR PROCEEDS OF ABOUT $3 MILLION Source text for Eikon: Further company coverage:
15h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
17h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET